Regenxbio Inc. (NASDAQ:RGNX) received a $25.00 target price from equities researchers at Piper Jaffray Cos. in a research note issued on Monday. The brokerage presently has a a “buy” rating on the stock. Piper Jaffray Cos.’s price target points to a potential upside of 40.29% from the company’s previous close.
A number of other equities analysts have also weighed in on the stock. Zacks Investment Research upgraded shares of Regenxbio from a “sell” rating to a “hold” rating in a research report on Friday, August 26th. Chardan Capital reiterated a “buy” rating on shares of Regenxbio in a research report on Monday, August 22nd. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $26.75.
Regenxbio (NASDAQ:RGNX) traded down 1.40% during midday trading on Monday, hitting $17.57. 199,446 shares of the stock traded hands. Regenxbio has a 12-month low of $7.07 and a 12-month high of $25.00. The firm’s market cap is $464.99 million. The company’s 50-day moving average is $13.90 and its 200 day moving average is $11.22.
Regenxbio (NASDAQ:RGNX) last posted its quarterly earnings data on Tuesday, August 9th. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.53) by $0.02. Regenxbio had a negative net margin of 451.73% and a negative return on equity of 17.89%. On average, analysts anticipate that Regenxbio will post ($2.37) EPS for the current fiscal year.
Several large investors have recently modified their holdings of the company. BlackRock Institutional Trust Company N.A. raised its stake in shares of Regenxbio by 90.6% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 58,821 shares of the company’s stock valued at $635,000 after buying an additional 27,960 shares during the last quarter. State Street Corp raised its stake in shares of Regenxbio by 53.0% in the first quarter. State Street Corp now owns 88,025 shares of the company’s stock valued at $950,000 after buying an additional 30,500 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Regenxbio by 16.9% in the first quarter. Geode Capital Management LLC now owns 57,142 shares of the company’s stock valued at $617,000 after buying an additional 8,255 shares during the last quarter. Sabby Management LLC raised its stake in shares of Regenxbio by 157.0% in the first quarter. Sabby Management LLC now owns 300,329 shares of the company’s stock valued at $3,244,000 after buying an additional 183,469 shares during the last quarter. Finally, Vivo Capital LLC bought a new stake in shares of Regenxbio during the first quarter valued at approximately $10,697,000. Institutional investors own 68.73% of the company’s stock.
REGENXBIO Inc is a biotechnology company. The Company is focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. Its AAV gene delivery platform (its NAV Technology Platform) consists of rights to over 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10 (NAV Vectors).
Receive News & Ratings for Regenxbio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.